From Nasdaq: 2025-06-11 00:56:00

Moderna’s stock (NASDAQ: MRNA) has plummeted over 80% in the past year due to challenges in vaccine sales. Lower projections in Europe and an underwhelming outlook led to a more than 20% drop after Q2 earnings. Revenue fell 83% to $3.1 billion, with further projections at $2.1 billion in 2025, exacerbating investor concerns.

The decline is mainly due to a sharp drop in demand for Moderna’s COVID-19 vaccine, impacting financials significantly. Recent developments, including lowered sales forecasts and delayed product timelines, have raised investor concerns. With a limited product portfolio heavily reliant on the COVID-19 vaccine, Moderna faces challenges in transitioning to a seasonal vaccine market.

Moderna’s Operating Income was $-3.7 Bil with an Operating Margin of -118.8%, while Operating Cash Flow was $-3.1 Bil with an OCF Margin of -97.2% over the last four quarters. The company is struggling to offset losses from declining COVID-19 vaccine sales, leading to a substantial drop in stock price.

Moderna capitalized on pandemic demand but now faces challenges in a normalized market. Diversifying revenue streams is crucial, as the rapid decline in vaccine sales outweighs the company’s ability to offset losses quickly. Investing in a diversified portfolio like the Trefis High Quality (HQ) strategy is essential for balancing risk and reward, outperforming major indices since inception.



Read more at Nasdaq: Why Moderna Stock Is Crumbling